← All trials
NCT04403100
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 28, 2020
- Primary completion
- Aug 28, 2020
- Completion date
- Nov 28, 2020
- First posted
- May 27, 2020
- Last posted
- May 27, 2020
- Enrollment
- 1968
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Cardresearch - Cardiologia Assistencial e de Pesquisa LTDALead sponsor
- Cardresearch - Cardiologia Assistencial e de Pesquisa LTDAReponsible party - principal investigator
- Cardresearch - Cardiologia Assistencial e de Pesquisa LTDAOverall official - principal investigator
- Cardresearch - Cardiologia Assistencial e de Pesquisa LTDACollaborator
- Cytel Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.